[Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].
A guinea pig model of experimental Pseudomonas aeruginosa pneumonia was used to evaluate factors affecting the efficacy of passive immune therapy with Psomaglobin N, a hyperimmune P. aeruginosa globulin. Animals treated 2 h after infection with a single intravenous infusion of Psomaglobin N, 500 mg/kg, demonstrated 33% survival. Lower dosages were less effective and no survivors occurred among albumin-treated controls. Treatment with Psomaglobin N was effective if given 2 h or 8 h after infection but not if delayed until 24 h after infection. Animals rendered neutropenic with cyclophosphamide did not survive if treated with Psomaglobin N alone. However, when Psomaglobin N was added to tobramycin treatment, a significant increase in survival occurred (86%) as compared to that observed with tobramycin alone (43%) (p less than 0.05). We conclude that Psomaglobin N may offer a useful therapeutic option in management of P. aeruginosa pneumonia.
D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D000918:Antibody Specificity; D006168:Guinea Pigs; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000627:therapeutic use; D009504:Neutrophils / Q000276:immunology; D011014:Pneumonia / Q000276:immunology / Q000628:therapy*; D011552:Pseudomonas Infections / Q000276:immunology / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G
Pseudomonas aeruginosa-Immunglobulin bei experimenteller Pneumonie.